Compare Amgen, Inc. (AMGN) vs Iron Mountain Inc (IRM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Iron Mountain Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Iron Mountain Inc trades at $121.55 (market cap $36.15B). The key difference: Amgen, Inc. is far larger — about 5.4× Iron Mountain Inc's market cap, and Iron Mountain Inc pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| AMGN | IRM | |
|---|---|---|
Market Cap | $196.12B | $36.15B |
Sector | Health | Real Estate |
52-Week High | $388.16 | $133.06 |
52-Week Low | $271.18 | $78.86 |
Enterprise Value | $241.41B | $55.29B |
Dividend Yield | 2.77% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Iron Mountain (IRM) trades at $121.50, up 1.69% today, with strong recent earnings beats and a bullish analyst consensus of 65% buy ratings. The stock shows a bearish technical signal but is supported by positive momentum in data center demand and a recent $1.5 billion debt offering. Revenue growth is steady, though net margins are thin at 3.76%, and the company carries high debt levels with a debt-to-asset ratio of 74.39% as of 2024.
Outlook is mixed: robust data center growth and dividend yield offer upside, but high valuation (P/E 132.08) and leverage pose risks. The consensus price target of $138.67 suggests 14% potential upside, yet technical resistance near $122 may limit near-term gains. Investors should weigh strong institutional support against elevated financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
